Tag: Johnson & Johnson
Cerenovus and Biosense Webster among brands newly incorporated into Johnson &...
Johnson & Johnson (J&J) recently shared that its medical technology businesses—including Cerenovus and Biosense Webster, as well as Abiomed, DePuy Synthes, and Ethicon—will now...
AF Symposium hears late-breaking data from RFA and PFA trials
Biosense Webster has announced an update and late-breaking data from trials across radiofrequency ablation (RFA) and pulsed field ablation (PFA) at the 2023 AF...
Biosense Webster announces first patients enrolled in post-market approval study for...
Johnson & Johnson have announced that Biosense Webster has received approval from the US Food and Drug Administration (FDA) for its VISITAG SURPOINT External...
New data demonstrates >90% year 1 success rate for radiofrequency ablation...
Biosense Webster, a Division of Johnson & Johnson Medical NV/SA, and a leader in the diagnosis and treatment of cardiac arrhythmias, recently presented new...